Developer docs
API playgroundTry for free, no card

Search company profiles

Zenflow

Full company profile

uuid0000bqc

Namestring
Zenflow
Legal namestring
Zenflow, Inc.
Websiteurl
zenflow.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Zenflow is a venture-backed medical device company headquartered in South San Francisco that develops minimally invasive implants for the treatment of benign prostatic hyperplasia (BPH). The company was founded out of the Stanford Byers Center for Biodesign and built a clinical evidence base across three trials covering more than 300 patients (Phase I Feasibility, Phase II ZEST Pilot, and Phase III BREEZE Pivotal IDE) before receiving FDA approval in December 2025 for its Spring Implant and Delivery System as a first-line interventional therapy for BPH.

The core product is a self-expanding nitinol implant delivered through a fully flexible scope using a balloon-anchor delivery system with HD visualization during release. Three implant size options enable anatomical customization, and the design is fully reversible without piercing, cutting, heating, or tissue removal. Clinical evidence highlights include a 0% device/procedure-related serious adverse event rate, 0% surgical reintervention through 12 months, 99% of men not requiring a post-procedure catheter, a 62% responder rate at one year with a mean 9-point IPSS improvement, and 100% preservation of sexual function. A companion single-use cystoscope received FDA 510(k) clearance in September 2025.

Zenflow's revenue model is hardware sales of the Spring Implant and Delivery System (and the companion cystoscope) directly to urology practices, hospitals, and ambulatory surgery centers, executed through an enterprise field-sales motion targeting urologists and supported by conference engagement (AUA, EAU) and key opinion leader advocacy. The company has raised approximately $48 million across disclosed funding rounds, including a $24 million Series B led by Invus Opportunities in 2021 and a $24 million Series C in November 2024 led by Cook Medical with participation from F-Prime, Invus Opportunities, MedTech Venture Partners, Golden Seeds, and Propel(X). Revenue is not yet recognized; the company is in pre-commercial preparation following December 2025 FDA approval.

Short descriptiontext

Zenflow is a South San Francisco medical device company that has developed and received FDA approval for the Spring Implant and Delivery System, a reversible, minimally invasive nitinol implant for treating benign prostatic hyperplasia, sold to urologists, hospitals, and ambulatory surgery centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
urology medical devices, BPH treatment devices, interventional urology, nitinol implants, minimally invasive implants
Industry1 code
PRIMARYHLAKAOAF
Endourology & Minimally Invasive Urologic Surgery
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Urology Medical Devices
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Spring Implant and Delivery System Sales
TypeHardware Sales
Description

Zenflow generates revenue through the sale of its FDA-approved Spring Implant and Delivery System to urology practices, hospitals, and other healthcare providers for the treatment of BPH. The device is a one-time implantable product used in a clinical procedure.

biospace.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Spring System
Description

Minimally invasive treatment for benign prostatic hyperplasia (BPH) - FDA approved implant and delivery system

zenflow.com
+2 more records
Core offering1 text field

Zenflow develops, manufactures, and commercializes the Spring Implant and Delivery System, an FDA-approved (December 2025) minimally invasive medical device for treating benign prostatic hyperplasia (BPH) in men. The self-expanding nitinol implant is delivered through a fully flexible scope with a balloon-anchor delivery system and is sold directly to urology practices, hospitals, and ambulatory surgery centers for use by urologists as a first-line interventional BPH therapy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 62% responder rate at 1 year with mean IPSS improvement of 37% (9 points)
+7 more records
Product overview1 text field

Zenflow offers a focused portfolio of medical devices for treating benign prostatic hyperplasia (BPH). The core offering is the Zenflow Spring Implant and Delivery System, an FDA-approved minimally invasive treatment. This system is supported by the companion Single-Use Cystoscope (FDA 510(k) cleared) for procedure delivery. Clinical validation comes from the ZEST Pilot Study (Phase II, 80+ patients) and the BREEZE Pivotal Study (Phase III, 200+ patients). The Spring System provides a reversible, tissue-preserving alternative to traditional BPH procedures, designed at Stanford Biodesign and now FDA-approved as a first-line interventional therapy.

Product and service2 records
1Zenflow Spring Implant and Delivery System
CategoryUrology medical device / BPH implant
Description

FDA-approved minimally invasive implant for treating benign prostatic hyperplasia (BPH) in men. The self-expanding nitinol implant is delivered through a fully flexible scope with a balloon-anchor delivery system and HD visualization, available in three size options for precise anatomical fit. The procedure requires no piercing, cutting, heating, or tissue removal, is fully reversible, and has demonstrated 0% surgical reintervention through 12 months, 0% device/procedure-related SAEs, 99% no post-procedure catheter, and 100% sexual function preservation in clinical trials.

2Single-Use Cystoscope
CategoryUrology medical device / procedure accessory
Description

FDA 510(k)-cleared first-of-its-kind single-use cystoscope used in conjunction with the Zenflow Spring Implant and Delivery System to enable the minimally invasive BPH treatment procedure.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFoundationalTypeStrategic or Co-development PartnerAnnounced on2014-01-01
Description

Zenflow was founded out of the Stanford Byers Center for Biodesign. The company states it was designed at Stanford Biodesign, reflecting deep origins in the Stanford innovation ecosystem. The Stanford Byers Center for Biodesign has helped innovators impact over a million patients, with Zenflow founders Shreya Mehta and Nick Damiano featured in its 'Million+ Patients Helped' program.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Teleflex acquired NeoTract and markets the Urolift System, a leading minimally invasive BPH implant. Urolift is the most established mechanical implant competitor to Zenflow's Spring and directly competes for the same urologist customers and BPH patient population.

TypeDirect peer
Description

Procept BioRobotics markets Aquablation, a robotic waterjet BPH treatment. As a fellow private/early-commercial minimally invasive BPH therapy company, it is one of the closest comparable growth-stage urology device businesses competing for the same first-line interventional therapy market.

TypeBroad incumbent
Description

Boston Scientific acquired NxThera and markets the Rezum System, a minimally invasive steam-based BPH treatment, and also acquired Lumenis. As a major urology incumbent with established sales channels and reimbursement infrastructure, it competes broadly for BPH patients and urologist mindshare.

TypeBroad incumbent
Description

Olympus acquired Medi-Tate and markets the iTind device, a temporarily implanted nitinol BPH treatment that is structurally similar to Zenflow's Spring. Olympus is also a major player in urology visualization (cystoscopes) used in BPH procedures, competing across both device and capital equipment categories.

TypeEmerging player
Description

Sonablate markets high-intensity focused ultrasound (HIFU) for BPH and other conditions. As another minimally invasive BPH therapy alternative, it represents an emerging non-implant treatment option competing for the same interventional therapy positioning.

6HistoSonics
TypeEmerging player
Description

HistoSonics is developing histotripsy (focused ultrasound tissue destruction) for prostate applications. While earlier stage, it represents a future non-invasive BPH treatment option that could compete with Zenflow's interventional positioning.

7Cook Medical
TypeOthers
Description

Cook Medical led Zenflow's Series C financing and is a major urology and medical device manufacturer. As a strategic investor and adjacent urology player, Cook provides both capital and potential strategic partnership/incumbent competitive dynamics relevant to Zenflow's commercialization.

TypeOthers
Description

F-Prime Capital is a healthcare-focused venture firm that has invested in both Zenflow and multiple other medical device companies. While not a direct competitor, F-Prime's portfolio includes urology and surgical device companies that are thematically comparable to Zenflow.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Zenflow

Urology Medical Deviceszenflow.com

Zenflow is a South San Francisco medical device company that has developed and received FDA approval for the Spring Implant and Delivery System, a reversible, minimally invasive nitinol implant for treating benign prostatic hyperplasia, sold to urologists, hospitals, and ambulatory surgery centers.

What Zenflow does

Zenflow is a venture-backed medical device company headquartered in South San Francisco that develops minimally invasive implants for the treatment of benign prostatic hyperplasia (BPH). The company was founded out of the Stanford Byers Center for Biodesign and built a clinical evidence base across three trials covering more than 300 patients (Phase I Feasibility, Phase II ZEST Pilot, and Phase III BREEZE Pivotal IDE) before receiving FDA approval in December 2025 for its Spring Implant and Delivery System as a first-line interventional therapy for BPH.

The core product is a self-expanding nitinol implant delivered through a fully flexible scope using a balloon-anchor delivery system with HD visualization during release. Three implant size options enable anatomical customization, and the design is fully reversible without piercing, cutting, heating, or tissue removal. Clinical evidence highlights include a 0% device/procedure-related serious adverse event rate, 0% surgical reintervention through 12 months, 99% of men not requiring a post-procedure catheter, a 62% responder rate at one year with a mean 9-point IPSS improvement, and 100% preservation of sexual function. A companion single-use cystoscope received FDA 510(k) clearance in September 2025.

Zenflow's revenue model is hardware sales of the Spring Implant and Delivery System (and the companion cystoscope) directly to urology practices, hospitals, and ambulatory surgery centers, executed through an enterprise field-sales motion targeting urologists and supported by conference engagement (AUA, EAU) and key opinion leader advocacy. The company has raised approximately $48 million across disclosed funding rounds, including a $24 million Series B led by Invus Opportunities in 2021 and a $24 million Series C in November 2024 led by Cook Medical with participation from F-Prime, Invus Opportunities, MedTech Venture Partners, Golden Seeds, and Propel(X). Revenue is not yet recognized; the company is in pre-commercial preparation following December 2025 FDA approval.

Zenflow firmographics

Firmographics
Name
Zenflow
Legal name
Zenflow, Inc.
Website
https://zenflow.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Zenflow is a South San Francisco medical device company that has developed and received FDA approval for the Spring Implant and Delivery System, a reversible, minimally invasive nitinol implant for treating benign prostatic hyperplasia, sold to urologists, hospitals, and ambulatory surgery centers.
Ownership category
akta.pro rank

Zenflow industry classification

Industry
Product category
Urology Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAKAOAF
Endourology & Minimally Invasive Urologic Surgery

Keywords

  • Urology medical devices
  • BPH treatment devices
  • Interventional urology
  • Nitinol implants
  • Minimally invasive implants

Where Zenflow is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Zenflow business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

  1. Spring Implant and Delivery System Sales: Zenflow generates revenue through the sale of its FDA-approved Spring Implant and Delivery System to urology practices, hospitals, and other healthcare providers for the treatment of BPH. The device is a one-time implantable product used in a clinical procedure.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Zenflow product offering

Product offering

Core offering

Zenflow develops, manufactures, and commercializes the Spring Implant and Delivery System, an FDA-approved (December 2025) minimally invasive medical device for treating benign prostatic hyperplasia (BPH) in men. The self-expanding nitinol implant is delivered through a fully flexible scope with a balloon-anchor delivery system and is sold directly to urology practices, hospitals, and ambulatory surgery centers for use by urologists as a first-line interventional BPH therapy.

Product overview

Zenflow offers a focused portfolio of medical devices for treating benign prostatic hyperplasia (BPH). The core offering is the Zenflow Spring Implant and Delivery System, an FDA-approved minimally invasive treatment. This system is supported by the companion Single-Use Cystoscope (FDA 510(k) cleared) for procedure delivery. Clinical validation comes from the ZEST Pilot Study (Phase II, 80+ patients) and the BREEZE Pivotal Study (Phase III, 200+ patients). The Spring System provides a reversible, tissue-preserving alternative to traditional BPH procedures, designed at Stanford Biodesign and now FDA-approved as a first-line interventional therapy.

Differentiator

Problem solved

Functional benefit

Brands

  • Spring System: Minimally invasive treatment for benign prostatic hyperplasia (BPH) - FDA approved implant and delivery system
  • Spring Implant
  • BREEZE Pivotal Clinical Trial

Products and services

  • Zenflow Spring Implant and Delivery System FDA-approved minimally invasive implant for treating benign prostatic hyperplasia (BPH) in men. The self-expanding nitinol implant is delivered through a fully flexible scope with a balloon-anchor delivery system and HD visualization, available in three size options for precise anatomical fit. The procedure requires no piercing, cutting, heating, or tissue removal, is fully reversible, and has demonstrated 0% surgical reintervention through 12 months, 0% device/procedure-related SAEs, 99% no post-procedure catheter, and 100% sexual function preservation in clinical trials.
  • Single-Use Cystoscope FDA 510(k)-cleared first-of-its-kind single-use cystoscope used in conjunction with the Zenflow Spring Implant and Delivery System to enable the minimally invasive BPH treatment procedure.

Quantifiable outcome

  • 62% responder rate at 1 year with mean IPSS improvement of 37% (9 points)
  • +7 more outcomes

Companies that use Zenflow

Customer profile

Segments3 records

Ideal customer profiles2 records

Zenflow technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Zenflow partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Stanford Byers Center for BiodesignfoundationalStrategic or Co-development Partner · 1 January 2014Zenflow was founded out of the Stanford Byers Center for Biodesign. The company states it was designed at Stanford Biodesign, reflecting deep origins in the Stanford innovation ecosystem. The Stanford Byers Center for Biodesign has helped innovators impact over a million patients, with Zenflow founders Shreya Mehta and Nick Damiano featured in its 'Million+ Patients Helped' program.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Zenflow competitors and assessment

Company assessment

Direct peers

  • Teleflex: Teleflex acquired NeoTract and markets the Urolift System, a leading minimally invasive BPH implant. Urolift is the most established mechanical implant competitor to Zenflow's Spring and directly competes for the same urologist customers and BPH patient population.
  • Procept BioRobotics: Procept BioRobotics markets Aquablation, a robotic waterjet BPH treatment. As a fellow private/early-commercial minimally invasive BPH therapy company, it is one of the closest comparable growth-stage urology device businesses competing for the same first-line interventional therapy market.

Broad incumbents

  • Boston Scientific: Boston Scientific acquired NxThera and markets the Rezum System, a minimally invasive steam-based BPH treatment, and also acquired Lumenis. As a major urology incumbent with established sales channels and reimbursement infrastructure, it competes broadly for BPH patients and urologist mindshare.
  • Olympus: Olympus acquired Medi-Tate and markets the iTind device, a temporarily implanted nitinol BPH treatment that is structurally similar to Zenflow's Spring. Olympus is also a major player in urology visualization (cystoscopes) used in BPH procedures, competing across both device and capital equipment categories.

Emerging players

  • Sonablate: Sonablate markets high-intensity focused ultrasound (HIFU) for BPH and other conditions. As another minimally invasive BPH therapy alternative, it represents an emerging non-implant treatment option competing for the same interventional therapy positioning.
  • HistoSonics: HistoSonics is developing histotripsy (focused ultrasound tissue destruction) for prostate applications. While earlier stage, it represents a future non-invasive BPH treatment option that could compete with Zenflow's interventional positioning.

Others

  • Cook Medical: Cook Medical led Zenflow's Series C financing and is a major urology and medical device manufacturer. As a strategic investor and adjacent urology player, Cook provides both capital and potential strategic partnership/incumbent competitive dynamics relevant to Zenflow's commercialization.
  • F-Prime Capital: F-Prime Capital is a healthcare-focused venture firm that has invested in both Zenflow and multiple other medical device companies. While not a direct competitor, F-Prime's portfolio includes urology and surgical device companies that are thematically comparable to Zenflow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Zenflow social profiles

Digital presence

Zenflow compliance and trust

Trust signal

Compliance2 records

Zenflow financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Zenflow leadership team

Management profile

Number of profiles

Profiles8 records

Zenflow funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Zenflow M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zenflow

What does Zenflow do?

Zenflow develops, manufactures, and commercializes the Spring Implant and Delivery System, an FDA-approved (December 2025) minimally invasive medical device for treating benign prostatic hyperplasia (BPH) in men. The self-expanding nitinol implant is delivered through a fully flexible scope with a balloon-anchor delivery system and is sold directly to urology practices, hospitals, and ambulatory surgery centers for use by urologists as a first-line interventional BPH therapy.

Is Zenflow a public or private company?

Zenflow is a private company. It is classified as venture growth investor backed and is currently operating.

When was Zenflow founded?

Zenflow was founded in 2014. It employs 11 to 50 people.

Where is Zenflow based?

Zenflow is headquartered in South San Francisco, United States, in the North America region.

How does Zenflow make money?

One revenue line is on record: spring Implant and Delivery System Sales.

Who are Zenflow's main competitors?

Direct peers on record are Teleflex and Procept BioRobotics. Broad incumbents are Boston Scientific and Olympus. Emerging players are Sonablate and HistoSonics. Others are Cook Medical and F-Prime Capital.

Does Zenflow have an API?

No public API is recorded for Zenflow.

What industry is Zenflow in?

Zenflow's product category is Urology Medical Devices. Its primary akta.pro industry code is HLAKAOAF, Endourology & Minimally Invasive Urologic Surgery. Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical Device NetworkZenflow raises $52m for BPH implant and inks US distribution pact with Cook MedicalZenflow raised $52m in a Series D round led by Cook Medical to commercialize its Spring BPH implant, which received FDA clearance in December 2025. Cook will lead US distribution for the device, which is inserted into the urethra to relieve obstructive symptoms while preserving sexual function.MedTech DiveZenflow raises $52M, inks distribution deal with Cook MedicalZenflow raised $52 million and signed a distribution deal with Cook Medical to commercialize its Zenflow Spring system for benign prostatic hyperplasia. The device, FDA-approved in December, showed 60% response in a pivotal trial versus 33% in sham control. Cook Medical will be the sole U.S. distributor.BioSpaceZenflow Announces U.S. Commercialization Progress with Four Centers Completing Zenflow Spring® Implant and Delivery System ProceduresZenflow announced its first commercial procedures with the Zenflow Spring implant and delivery system for BPH treatment, with the first procedure performed on July 29, 2026. The FDA-approved device showed a 37% mean IPSS improvement in the BREEZE trial, with 99% of patients avoiding post-procedure catheterization.Urology TimesDean Elterman, MD, MSc, FRCSC, discusses BREEZE and ZEST data for ZenflowDean Elterman, a urology professor at the University of Toronto, discusses clinical data from the BREEZE and ZEST studies regarding the Zenflow Spring System for treating benign prostatic hyperplasia. The discussion focuses on patient selection criteria, procedural workflow, and the durability and efficacy of the device.Urology TimesDean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic SpringDr. Dean Elterman presented efficacy and safety data from the pivotal BREEZE trial regarding the Zenflow Prostatic Spring at the 2026 American Urological Association Annual Meeting in Washington, DC. The results demonstrated that the device significantly improved lower urinary tract symptoms associated with benign prostatic hyperplasia while maintaining a favorable safety profile.Urology TimesDean Elterman, MD, shares 3-year data on Zenflow Spring System for BPHData from a 3-year study on the Zenflow Spring System for treating benign prostatic hyperplasia (BPH) was presented at the 2025 American Urological Association Annual Meeting in Las Vegas. The study reported significant improvements in symptom scores and quality of life for patients, with a 74% responder rate, suggesting the system's efficacy and minimal invasiveness. The Zenflow Spring System is currently being evaluated in the ongoing BREEZE trial, which includes participants from the US and Canada.Urology TimesBilal Chughtai, MD, discusses cystoscopic outcomes with the Zenflow Spring SystemBilal I. Chughtai, MD, presented 12-month cystoscopic data from the pivotal IDE trial of the Zenflow Spring System at the 2026 American Urological Association Annual Meeting in Washington, DC. The findings indicated no statistically significant negative impact on efficacy outcomes, reinforcing the implant's long-term durability and biocompatibility. The Zenflow Spring System was cleared in December 2025 for managing lower urinary tract symptoms associated with benign prostatic hyperplasia.Urology TimesZenflow explained: A non-ablative, reversible approach to BPHDean Elterman, a urology professor at the University of Toronto, discusses Zenflow, a shape-memory prostate stent designed as a non-ablative and reversible treatment for benign prostatic obstruction. The article highlights the device's distinct material science and mechanism of action as key differentiators in managing lower urinary tract symptoms.Urology TimesDr. Chin discusses advantages of Zenflow Spring System for BPHDr. Chin discussed the findings of a study on the Zenflow Spring System for treating benign prostatic hyperplasia (BPH), presented at the 2021 American Urological Association Annual Meeting. The study highlighted the advantages of this investigational nitinol implant in treating BPH. The discussion sheds light on the evolving technology in urology that may benefit patients suffering from this condition.Urology TimesZenflow Spring System shows promising results in early trials for patients with BPHThe Zenflow Spring System is an investigational device designed for the treatment of benign prostatic hyperplasia (BPH), showing promising results in early trials presented at the 2021 American Urological Association Annual Meeting. The device, made of nitinol, offers advantages such as minimal invasiveness and good durability, reportedly lasting up to three years. A pivotal trial named BREEZE is planned to further assess its efficacy and support FDA clearance.